Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 52 | 2023 | 149 | 14.360 |
Why?
|
| Anti-Asthmatic Agents | 17 | 2023 | 31 | 4.870 |
Why?
|
| Hypersensitivity | 7 | 2023 | 37 | 2.590 |
Why?
|
| Physicians | 6 | 2022 | 103 | 2.570 |
Why?
|
| Adrenal Cortex Hormones | 13 | 2023 | 95 | 2.520 |
Why?
|
| Telemedicine | 7 | 2023 | 84 | 2.460 |
Why?
|
| Medication Adherence | 12 | 2023 | 49 | 2.270 |
Why?
|
| Patient Education as Topic | 9 | 2021 | 120 | 2.240 |
Why?
|
| Burnout, Professional | 4 | 2022 | 26 | 2.190 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 76 | 1.920 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 79 | 1.910 |
Why?
|
| Humans | 75 | 2023 | 22592 | 1.590 |
Why?
|
| Child | 29 | 2023 | 1148 | 1.580 |
Why?
|
| Community Health Workers | 7 | 2022 | 35 | 1.330 |
Why?
|
| Administration, Inhalation | 14 | 2022 | 35 | 1.260 |
Why?
|
| Adolescent | 24 | 2023 | 1855 | 1.200 |
Why?
|
| Pandemics | 10 | 2022 | 198 | 1.040 |
Why?
|
| Behavior Therapy | 2 | 2017 | 85 | 0.950 |
Why?
|
| Caregivers | 7 | 2019 | 185 | 0.910 |
Why?
|
| Nebulizers and Vaporizers | 8 | 2022 | 19 | 0.870 |
Why?
|
| Mobile Applications | 2 | 2020 | 27 | 0.780 |
Why?
|
| Betacoronavirus | 5 | 2020 | 66 | 0.770 |
Why?
|
| Emergency Service, Hospital | 8 | 2020 | 249 | 0.750 |
Why?
|
| Biological Products | 1 | 2022 | 31 | 0.730 |
Why?
|
| Environmental Exposure | 2 | 2018 | 18 | 0.660 |
Why?
|
| Allergy and Immunology | 4 | 2020 | 5 | 0.660 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 16 | 0.660 |
Why?
|
| Poverty | 3 | 2020 | 82 | 0.650 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 1019 | 0.650 |
Why?
|
| Adult | 18 | 2023 | 6826 | 0.630 |
Why?
|
| Female | 30 | 2023 | 12734 | 0.610 |
Why?
|
| Male | 29 | 2023 | 12260 | 0.590 |
Why?
|
| Parents | 2 | 2018 | 107 | 0.590 |
Why?
|
| Emigrants and Immigrants | 2 | 2018 | 19 | 0.580 |
Why?
|
| Health Literacy | 4 | 2021 | 83 | 0.570 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 36 | 0.570 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 6 | 0.570 |
Why?
|
| Registries | 1 | 2019 | 153 | 0.560 |
Why?
|
| Self Care | 5 | 2020 | 86 | 0.540 |
Why?
|
| Decision Making | 1 | 2018 | 174 | 0.510 |
Why?
|
| Child, Preschool | 8 | 2022 | 561 | 0.500 |
Why?
|
| Assertiveness | 1 | 2015 | 7 | 0.480 |
Why?
|
| Urban Population | 5 | 2013 | 124 | 0.450 |
Why?
|
| Chicago | 7 | 2019 | 788 | 0.450 |
Why?
|
| Social Support | 2 | 2021 | 174 | 0.420 |
Why?
|
| Family | 3 | 2021 | 85 | 0.410 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 10 | 0.400 |
Why?
|
| Patient Compliance | 2 | 2011 | 142 | 0.390 |
Why?
|
| Minority Groups | 4 | 2019 | 67 | 0.390 |
Why?
|
| MP3-Player | 2 | 2013 | 5 | 0.390 |
Why?
|
| United States | 7 | 2023 | 1741 | 0.380 |
Why?
|
| House Calls | 3 | 2021 | 15 | 0.370 |
Why?
|
| Electronics | 2 | 2021 | 9 | 0.360 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 83 | 0.350 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 35 | 0.350 |
Why?
|
| Computer Security | 2 | 2020 | 5 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 145 | 0.330 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 14 | 0.330 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 244 | 0.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 218 | 0.320 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2009 | 1 | 0.300 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 15 | 0.300 |
Why?
|
| Athletes | 1 | 2009 | 52 | 0.290 |
Why?
|
| Communication Barriers | 1 | 2007 | 3 | 0.280 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 164 | 0.280 |
Why?
|
| Quality Improvement | 3 | 2018 | 127 | 0.270 |
Why?
|
| Hospitalization | 2 | 2020 | 281 | 0.270 |
Why?
|
| Language | 1 | 2007 | 58 | 0.270 |
Why?
|
| Research Design | 2 | 2019 | 152 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 800 | 0.240 |
Why?
|
| Electronic Health Records | 3 | 2020 | 64 | 0.230 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 64 | 0.220 |
Why?
|
| Albuterol | 4 | 2022 | 14 | 0.210 |
Why?
|
| One Health | 1 | 2023 | 1 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 24 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 32 | 0.200 |
Why?
|
| Middle Aged | 7 | 2021 | 7800 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2020 | 58 | 0.200 |
Why?
|
| Health Status Disparities | 1 | 2023 | 58 | 0.200 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 119 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 42 | 0.190 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 752 | 0.180 |
Why?
|
| Anaphylaxis | 1 | 2021 | 11 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 4 | 0.180 |
Why?
|
| Endpoint Determination | 1 | 2021 | 21 | 0.170 |
Why?
|
| Depression | 3 | 2020 | 368 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 92 | 0.170 |
Why?
|
| Mental Health | 2 | 2020 | 95 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 33 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2021 | 2915 | 0.170 |
Why?
|
| Self Report | 1 | 2021 | 192 | 0.170 |
Why?
|
| Self-Management | 2 | 2017 | 11 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 2 | 2021 | 5 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2020 | 3 | 0.170 |
Why?
|
| Confidentiality | 1 | 2020 | 4 | 0.170 |
Why?
|
| Clinical Coding | 1 | 2020 | 5 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 189 | 0.170 |
Why?
|
| Tiotropium Bromide | 1 | 2020 | 2 | 0.170 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 3 | 0.170 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 4 | 0.170 |
Why?
|
| Lung | 1 | 2021 | 135 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 18 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 33 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2019 | 166 | 0.160 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 1 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 117 | 0.160 |
Why?
|
| Family Relations | 1 | 2019 | 12 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 168 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 11 | 0.150 |
Why?
|
| Documentation | 1 | 2019 | 20 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 68 | 0.150 |
Why?
|
| Pediatrics | 1 | 2019 | 38 | 0.150 |
Why?
|
| Prevalence | 2 | 2018 | 372 | 0.140 |
Why?
|
| Patient Participation | 1 | 2018 | 43 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2018 | 17 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 1955 | 0.140 |
Why?
|
| Volunteers | 1 | 2017 | 3 | 0.140 |
Why?
|
| Community Participation | 1 | 2017 | 12 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 24 | 0.130 |
Why?
|
| Education, Distance | 1 | 2017 | 15 | 0.130 |
Why?
|
| Cell Phone | 1 | 2017 | 6 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2016 | 23 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 311 | 0.120 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 15 | 0.120 |
Why?
|
| Health Status | 3 | 2021 | 201 | 0.110 |
Why?
|
| Smartphone | 1 | 2015 | 14 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2023 | 371 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2021 | 537 | 0.100 |
Why?
|
| Animals | 2 | 2023 | 3238 | 0.100 |
Why?
|
| Peer Group | 1 | 2013 | 32 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 557 | 0.100 |
Why?
|
| Housing | 1 | 2013 | 15 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 161 | 0.100 |
Why?
|
| Immunization, Passive | 2 | 2023 | 6 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 288 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 242 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2954 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 373 | 0.090 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2012 | 8 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2017 | 369 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 623 | 0.090 |
Why?
|
| School Health Services | 1 | 2011 | 18 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 51 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 122 | 0.090 |
Why?
|
| Students | 1 | 2011 | 37 | 0.090 |
Why?
|
| Consensus | 2 | 2021 | 81 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 26 | 0.080 |
Why?
|
| Aged | 2 | 2020 | 7300 | 0.080 |
Why?
|
| Anti-Allergic Agents | 1 | 2010 | 2 | 0.080 |
Why?
|
| Androstadienes | 1 | 2010 | 8 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 8 | 0.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 6 | 0.080 |
Why?
|
| Acetates | 1 | 2010 | 16 | 0.080 |
Why?
|
| Anxiety | 2 | 2021 | 143 | 0.080 |
Why?
|
| Puerto Rico | 3 | 2014 | 12 | 0.080 |
Why?
|
| Allergens | 2 | 2023 | 16 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 25 | 0.070 |
Why?
|
| Young Adult | 3 | 2020 | 1607 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 350 | 0.070 |
Why?
|
| Music | 1 | 2008 | 19 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2021 | 31 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 13 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2019 | 9 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 1476 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 13 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 43 | 0.050 |
Why?
|
| Irritants | 1 | 2023 | 1 | 0.050 |
Why?
|
| Community-Based Participatory Research | 2 | 2014 | 32 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 67 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 3 | 0.050 |
Why?
|
| Dry Powder Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Metered Dose Inhalers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Patients | 1 | 2022 | 31 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cytokines | 1 | 2023 | 200 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 223 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 54 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 42 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 8 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 23 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 88 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 90 | 0.040 |
Why?
|
| London | 1 | 2020 | 2 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 27 | 0.040 |
Why?
|
| Terbutaline | 1 | 2020 | 1 | 0.040 |
Why?
|
| Self Administration | 1 | 2020 | 16 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2020 | 7 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 29 | 0.040 |
Why?
|
| Professionalism | 1 | 2020 | 3 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 6 | 0.040 |
Why?
|
| Guilt | 1 | 2020 | 5 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 20 | 0.040 |
Why?
|
| Suicide | 1 | 2020 | 12 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 15 | 0.040 |
Why?
|
| Grief | 1 | 2020 | 18 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 105 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 27 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 50 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 65 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 314 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 269 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 65 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 46 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 78 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 98 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 120 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 96 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 45 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 127 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 55 | 0.040 |
Why?
|
| Health Promotion | 1 | 2020 | 122 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 209 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 217 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 161 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 517 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 423 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 79 | 0.030 |
Why?
|
| Persuasive Communication | 1 | 2017 | 1 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 22 | 0.030 |
Why?
|
| Sinusitis | 1 | 2019 | 150 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 29 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 53 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 72 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 105 | 0.030 |
Why?
|
| Schools | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2013 | 6 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Saliva | 1 | 2013 | 48 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 40 | 0.020 |
Why?
|
| Work of Breathing | 1 | 2012 | 4 | 0.020 |
Why?
|
| Vital Signs | 1 | 2012 | 3 | 0.020 |
Why?
|
| Spirometry | 1 | 2012 | 9 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 161 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 208 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 205 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 102 | 0.020 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2010 | 1 | 0.020 |
Why?
|
| Sulfides | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2010 | 26 | 0.020 |
Why?
|
| Illinois | 1 | 2009 | 216 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 379 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 431 | 0.010 |
Why?
|
| Vietnam | 1 | 1993 | 7 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 150 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 227 | 0.010 |
Why?
|
| Alcoholism | 1 | 1993 | 62 | 0.010 |
Why?
|
| Veterans | 1 | 1993 | 86 | 0.010 |
Why?
|